actoxumab + bezlotoxumab

Actoxumab and bezlotoxumab are fully human monoclonal antibodies developed for the prevention of recurrence of *Clostridium difficile* infection (CDI). Actoxumab targets and neutralizes *C. difficile* toxin A (TcdA), while bezlotoxumab targets and neutralizes *C. difficile* toxin B (TcdB). By binding to their respective toxins, these antibodies prevent the toxins from attaching to target cells, thereby blocking the cellular intoxication cascade that leads to inflammation and pathogenesis in CDI. The combination was developed by Medarex, University of Massachusetts Medical School, Bristol Myers Squibb, and Merck & Co. Clinical trials showed that co-administration reduced CDI recurrence in animal models and humans; however, phase III data indicated no additional benefit from combining both compared to bezlotoxumab alone[1][7][8].

Other names

actoxumab/bezlotoxumab